The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with FLOT chemotherapy as the first and only perioperative immunotherapy for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. Approval is based on the Phase III MATTERHORN trial, which demonstrated a 29% reduction in risk of progression, recurrence, or death and […]

Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration of targeting “undruggable” KRAS mutations. Meanwhile, durvalumab plus FLOT (D-FLOT) and zolbetuximab are reshaping treatment paradigms in gastroesophageal cancers with improved survival outcomes. Expert Commentary Scope & Focus Key Clinical Developments Pan-RAS Inhibitors in Pancreatic […]

Total neoadjuvant therapy with FLOT may optimize outcomes, but ctDNA could guide personalized treatment decisions.